Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083434 · ClinicalTrials.gov registry record · Phase 3
Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
A Phase 3 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Terminated
- Registry status
- Phase 3
- Development phase
NCT00083434 is a Phase 3 study that was terminated before completion, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
The verdict
NCT00083434, a Phase 3 study, was terminated before completion, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- TERMINATED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of this study is to examine the effectiveness of epoetin alfa in treating anemia in patients who have cancer or who no longer have any signs of the cancer, but remain anemic as a result of their treatment.
Interventions
- DRUG Epoetin alfa
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-02 |
| Est. Completion | 2004-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00083434
The ClinicalTrials.gov registry entry for NCT00083434 describes a study currently listed as terminated, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Epoetin alfa is the first listed.
NCT00083434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00083434 about?
NCT00083434 is a clinical study titled "Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy". The purpose of this study is to examine the effectiveness of epoetin alfa in treating anemia in patients who have cancer or who no longer have any signs of the cancer, but remain anemic as a result of their treatment.
What is the current status of trial NCT00083434?
This trial is currently terminated. It is a Phase 3 study. The study started on 2004-02. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00083434?
The interventions under investigation include: Epoetin alfa (DRUG).
Who is sponsoring clinical trial NCT00083434?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.